{"title":"Prevalence and Impact of Relapse in Patients With Schizophrenia.","authors":"John Lauriello","doi":"10.4088/JCP.MS19053BR1C","DOIUrl":null,"url":null,"abstract":"<p><p>Many individuals with schizophrenia experience multiple relapses, which are associated with serious and potentially fatal outcomes. Nonadherence to antipsychotic medications is a major contributor to relapse. By using reliable strategies to measure adherence and identify patients who are not taking their medications as prescribed, clinicians can intervene to possibly prevent relapse or decrease its severity.</p>","PeriodicalId":50234,"journal":{"name":"Journal of Clinical Psychiatry","volume":"81 2","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2020-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4088/JCP.MS19053BR1C","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 8
Abstract
Many individuals with schizophrenia experience multiple relapses, which are associated with serious and potentially fatal outcomes. Nonadherence to antipsychotic medications is a major contributor to relapse. By using reliable strategies to measure adherence and identify patients who are not taking their medications as prescribed, clinicians can intervene to possibly prevent relapse or decrease its severity.
期刊介绍:
For over 75 years, The Journal of Clinical Psychiatry has been a leading source of peer-reviewed articles offering the latest information on mental health topics to psychiatrists and other medical professionals.The Journal of Clinical Psychiatry is the leading psychiatric resource for clinical information and covers disorders including depression, bipolar disorder, schizophrenia, anxiety, addiction, posttraumatic stress disorder, and attention-deficit/hyperactivity disorder while exploring the newest advances in diagnosis and treatment.